← FDA DRUG APPROVALS

FDA ANDA · ANDA202599

ONDANSETRON

ondansetron hydrochloride

Sponsor: EUGIA PHARMA

APPLICATION
ANDA202599
TYPE
ANDA
ORIGINAL APPROVAL
2012-12-21
LATEST ACTION
2022-03-01
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

ONDANSETRON HYDROCHLORIDEDiscontinued
ONDANSETRON HYDROCHLORIDE EQ 2MG BASE/ML · INJECTABLE · INJECTION

Approval history

2022-03-01Labeling · Supplement 9 · standardAP
2021-08-19Labeling · Supplement 6 · standardAP
2021-08-19Labeling · Supplement 8 · standardAP
2015-01-17Labeling · Supplement 5 · standardAP
2015-01-17Labeling · Supplement 3 · standardAP
2012-12-21UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →